We found that CP11 reduced cholestanol-induced α-syn pathology and degeneration of dopaminergic neurons, suggesting that AEP inhibitors are promising for the treatment of parkinsonism induced by cholestanol. The gene discussed is LGMN; the disease is Parkinsonism.